GlaxoSmithKline PLC Press Releases

GSK 
$52.51
*  
0.31
 negative 
0.59%
Get GSK Alerts
*Delayed - data as of Apr. 17, 2014 
Exchange: NYSE
Industry: Health Care
Community Rating:
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save stocks for next time
Viewing
Filtered By
Ordered By

GSK and Genmab receive FDA approval for Arzerra® (ofatumumab) as first-line treatment in combination with chlorambucil for patients with Chronic Lymphocytic Leukaemia (CLL) for whom fludarabine-based therapy is considered inappropriate
4/17/2014 5:24:00 PM - PR Newswire

GSK receives US approval for once-weekly type 2 diabetes treatment, Tanzeum™ (albiglutide)
4/15/2014 2:26:00 PM - PR Newswire

Equities to Watch in the Health Care Sector -- Research on AbbVie, GlaxoSmithKline, AstraZeneca, and Novartis
4/9/2014 9:46:00 AM - PR Newswire

Update on GSK’S MAGE-A3 Cancer Immunotherapeutic Phase 3 Study in Non-Small Cell Lung Cancer
4/2/2014 2:01:00 AM - Business Wire

ViiV Healthcare announces new initiatives to improve access to dolutegravir: licence to the Medicines Patent Pool
4/1/2014 2:30:00 PM - PR Newswire

Health Care Sector Equities Technical Commentary -- Research on AbbVie, GlaxoSmithKline, AstraZeneca and Novartis
3/21/2014 6:44:00 PM - PR Newswire

GSK’s MAGE-A3 Cancer Immunotherapeutic Phase 3 Study in Non-Small Cell Lung Cancer Misses First Co-Primary Endpoints
3/20/2014 3:01:00 AM - Business Wire

ViiV Healthcare Announces Next Round of the Positive Action Southern Initiative to Support Linkages to HIV/AIDS Care and Treatment Adherence
3/19/2014 9:45:00 AM - PR Newswire

GSK and Theravance Announce Positive Results From Studies Comparing ANORO(TM) ELLIPTA(TM) With SERETIDE(R) DISKUS(R) and ADVAIR(R) DISKUS(R) in Patients With COPD
3/14/2014 8:00:00 AM - Market Wire

Appointments, Regulatory Approvals, Conference Participation Schedule, Acquisitions, and Increased Stake - Analyst Notes on Perrigo, Zoetis, ISIS, GSK, and AstraZeneca
3/13/2014 8:31:00 AM - PR Newswire

Patient Recruitment Completes in Landmark RELVAR(R)/BREO(R) ELLIPTA(R) Study to Understand Mortality and MorbidITy (SUMMIT) in COPD
3/13/2014 8:00:00 AM - Market Wire

Ligand Partner GlaxoSmithKline Submits U.S. Regulatory Application for Promacta® (eltrombopag) for Severe Aplastic Anaemia
2/28/2014 9:57:00 AM - Business Wire

Ligand Partner GlaxoSmithKline Gains FDA Breakthrough Therapy Designation for Promacta®/Revolade® for Severe Aplastic Anemia
2/3/2014 7:30:00 AM - Business Wire

ViiV Healthcare's new HIV medicine Tivicay™ (dolutegravir) is approved in Europe
1/21/2014 6:52:00 AM - PR Newswire